Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.37 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113109 | 0.93 | PPARG (0.51) | PPARGEPHX2TSHRLMNAP2RX7 | |
| SCHEMBL5120428 | 0.92 | PPARG (0.58) | PPARGEPHX2TSHRP2RX7RECQL | |
| SCHEMBL5110656 | 0.92 | EPHX2 (0.42) | PPARGEPHX2TSHRLMNAMAPK1 | |
| SCHEMBL5115472 | 0.88 | PPARG (0.59) | PPARGEPHX2TSHRP2RX7TEAD2 | |
| SCHEMBL5113135 | 0.85 | PPARG (0.45) | PPARGEPHX2TSHRLMNAP2RX7 | |
| SCHEMBL5110205 | 0.84 | TSHR (0.44) | PPARGEPHX2TSHRLMNAMAPK1 | |
| SCHEMBL5118776 | 0.82 | PTGDR2 (0.41) | PPARGEPHX2LMNA | |
| SCHEMBL5107718 | 0.81 | PPARG (0.48) | PPARGLMNANLRP1SMN1; SMN2 | |
| SCHEMBL5112185 | 0.81 | EPHX2 (0.43) | PPARGEPHX2TSHRLMNAP2RX7 | |
| SCHEMBL5121206 | 0.81 | TSHR (0.45) | PPARGEPHX2TSHRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885EPHX2 2573/4885TSHR 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.